Rapamycins: Mechanisms of Action and Cellular Resistance

Rapamycins are macrocyclic lactones that possess immunosuppressive, antifungal and antitumor properties. The parent compound, rapamycin, is approved as an immunosuppressive agent for preventing rejection in patients receiving organ transplantation. Two analogues, CCI-779 and RAD001 are currently being investigated as anticancer agents. Rapamycins first bind a cyclophilin FKBP12, and this complex binds and inhibits the function of mTOR (mammalian target of rapamycin) a serine/threonine (Ser/Thr) kinase with homology to phosphatidylinositol 3’ kinase. Currently, as mTOR is the only identified target, this places rapamycins in a unique position of being the most selective kinase inhibitor known. Consequently these agents have been powerful tools in elucidating the role of mTOR in cellular growth, proliferation, survival and tumorigenesis. Increasing evidence suggests that mTOR acts as a central controller sensing cellular environment (nutritional status or mitogenic stimulation) and regulating translation initiation through the eukaryotic initiation factor 4E, and ribosomal p70 S6 kinase pathways. Here we review the conserved TOR signaling pathways, conceptual basis for tumor selectivity, and the mechanisms of resistance to this class of antitumor agent.

[1]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.

[2]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. , 1975, The Journal of antibiotics.

[3]  J. Douros,et al.  New antitumor substances of natural origin. , 1981, Cancer treatment reviews.

[4]  D. Houchens,et al.  Human brain tumor xenografts in nude mice as a chemotherapy model. , 1983, European journal of cancer & clinical oncology.

[5]  S. Sehgal,et al.  Activity of rapamycin (AY-22,989) against transplanted tumors. , 1984, The Journal of antibiotics.

[6]  S. Thiru,et al.  RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTING , 1989, The Lancet.

[7]  S. Schreiber,et al.  Chemistry and biology of the immunophilins and their immunosuppressive ligands. , 1991, Science.

[8]  J. Heitman,et al.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast , 1991, Science.

[9]  T. Hultsch,et al.  The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines. , 1992, Molecular biology of the cell.

[10]  M. Mclaughlin,et al.  Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity , 1993, Molecular and cellular biology.

[11]  M. Mclaughlin,et al.  The tyrosine89 residue of yeast FKBP12 is required for rapamycin binding. , 1993, Gene.

[12]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[13]  M. Mclaughlin,et al.  Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. , 1994, The Journal of biological chemistry.

[14]  A. Nairn,et al.  Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  James M. Roberts,et al.  lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin , 1994, Nature.

[16]  C. Thompson,et al.  Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Shantz,et al.  Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. , 1994, Cancer research.

[18]  J. Blenis,et al.  Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma. , 1995, Cellular immunology.

[19]  D. Fruman,et al.  FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells , 1995, European journal of immunology.

[20]  N. Sonenberg,et al.  Eukaryotic Translation Initiation Factor 4E Regulates Expression of Cyclin D1 at Transcriptional and Post-transcriptional Levels (*) , 1995, The Journal of Biological Chemistry.

[21]  G. Mills,et al.  Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. , 1995, Cancer research.

[22]  J. Heitman,et al.  TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin (*) , 1995, The Journal of Biological Chemistry.

[23]  S. Schreiber,et al.  Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Heitman,et al.  FKBP12‐rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol‐4 kinase activity. , 1995, The EMBO journal.

[25]  S. Muthukkumar,et al.  RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL DEATH IN B LYMPHOMA CELLS , 1995, Transplantation.

[26]  M. Lovett,et al.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.

[27]  J. Massagué,et al.  Rapamycin resistance tied to defective regulation of p27Kip1 , 1996, Molecular and cellular biology.

[28]  E. Gelfand,et al.  p70 S6 kinase sensitivity to rapamycin is eliminated by amino acid substitution of Thr229. , 1996, Journal of immunology.

[29]  Missense mutations at the FKBP12-rapamycin-binding site of TOR1. , 1996, Gene.

[30]  T. Seufferlein,et al.  Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. , 1996, Cancer research.

[31]  T. Chambers,et al.  Role of the Stress-activated/c-Jun NH2-terminal Protein Kinase Pathway in the Cellular Response to Adriamycin and Other Chemotherapeutic Drugs* , 1996, The Journal of Biological Chemistry.

[32]  D. Templeton,et al.  Constitutive activation of S6 kinase by deletion of amino-terminal autoinhibitory and rapamycin sensitivity domains , 1996, Molecular and cellular biology.

[33]  K. Arndt,et al.  Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases. , 1996, Genes & development.

[34]  Y. Shiloh,et al.  Rapamycin resistance in ataxia-telangiectasia. , 1996, Oncogene.

[35]  M. Kasuga,et al.  Regulation of eIF-4E BP1 Phosphorylation by mTOR* , 1997, The Journal of Biological Chemistry.

[36]  A. De Benedetti,et al.  Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma , 1997, Cancer.

[37]  T. Ishizuka,et al.  Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells. , 1997, Biochemical and biophysical research communications.

[38]  D. Brautigan,et al.  B cell receptor-associated protein alpha4 displays rapamycin-sensitive binding directly to the catalytic subunit of protein phosphatase 2A. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Gingras,et al.  The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k , 1997, Molecular and cellular biology.

[40]  Christine C. Hudson,et al.  Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. , 1997, Science.

[41]  H. Sanjo,et al.  Ig receptor binding protein 1 (alpha4) is associated with a rapamycin-sensitive signal transduction in lymphocytes through direct binding to the catalytic subunit of protein phosphatase 2A. , 1998, Blood.

[42]  P. Houghton,et al.  Studies on the mechanism of resistance to rapamycin in human cancer cells. , 1998, Molecular pharmacology.

[43]  Stefano Fumagalli,et al.  Disruption of the p70s6k/p85s6k gene reveals a small mouse phenotype and a new functional S6 kinase , 1998, The EMBO journal.

[44]  S. Desrivières,et al.  Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability* , 1998, The Journal of Biological Chemistry.

[45]  S. Sehgal.  Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. , 1998, Clinical biochemistry.

[46]  S. Snyder,et al.  RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  A. Shaw,et al.  The 14-3-3 proteins positively regulate rapamycin-sensitive signaling , 1998, Current Biology.

[48]  K. Tomizawa,et al.  Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells. , 1998, Biochemical and biophysical research communications.

[49]  A. Schmidt,et al.  The TOR nutrient signalling pathway phosphorylates NPR1 and inhibits turnover of the tryptophan permease , 1998, The EMBO journal.

[50]  J. Broach,et al.  Tor proteins and protein phosphatase 2A reciprocally regulate Tap42 in controlling cell growth in yeast , 1999, The EMBO journal.

[51]  Linda N. Liu,et al.  Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. , 1999, Cancer research.

[52]  J. Ruppert,et al.  The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[53]  J. Heitman,et al.  The TOR signaling cascade regulates gene expression in response to nutrients. , 1999, Genes & development.

[54]  G. Thomas,et al.  Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. , 1999, Current opinion in genetics & development.

[55]  A. De Benedetti,et al.  Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  T. Powers,et al.  Regulation of ribosome biogenesis by the rapamycin-sensitive TOR-signaling pathway in Saccharomyces cerevisiae. , 1999, Molecular biology of the cell.

[57]  S. Gygi,et al.  Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. , 1999, Genes & development.

[58]  A. De Benedetti,et al.  eIF4E expression in tumors: its possible role in progression of malignancies. , 1999, The international journal of biochemistry & cell biology.

[59]  S. Schreiber,et al.  Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[60]  A. Schmidt,et al.  Starvation Induces Vacuolar Targeting and Degradation of the Tryptophan Permease in Yeast , 1999, The Journal of cell biology.

[61]  T. Seufferlein,et al.  Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. , 1999, Cancer research.

[62]  J. Fando,et al.  4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. , 2000, The international journal of biochemistry & cell biology.

[63]  O. Shah,et al.  4E-BP1 and S6K1: translational integration sites for nutritional and hormonal information in muscle. , 2000, American journal of physiology. Endocrinology and metabolism.

[64]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[65]  Multiple Mechanisms Control Phosphorylation of PHAS-I in Five (S/T)P Sites That Govern Translational Repression , 2000, Molecular and Cellular Biology.

[66]  M. Hidalgo,et al.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy , 2000, Oncogene.

[67]  R. Abraham,et al.  Mammalian Target of Rapamycin-dependent Phosphorylation of PHAS-I in Four (S/T)P Sites Detected by Phospho-specific Antibodies* , 2000, The Journal of Biological Chemistry.

[68]  Kazuya Nagano,et al.  Tor-Mediated Induction of Autophagy via an Apg1 Protein Kinase Complex , 2000, The Journal of cell biology.

[69]  M. Kastan,et al.  Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1 , 2000, Nature Cell Biology.

[70]  S. Volarevic,et al.  Role of S6 phosphorylation and S6 kinase in cell growth. , 2001, Progress in nucleic acid research and molecular biology.

[71]  M. Mann,et al.  Cell Cycle Protein Expression in Vascular Smooth Muscle Cells In Vitro and In Vivo Is Regulated Through Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[72]  K. Arndt,et al.  TIP41 interacts with TAP42 and negatively regulates the TOR signaling pathway. , 2001, Molecular cell.

[73]  M. Mann,et al.  p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Shile Huang,et al.  p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. , 2001, Cancer research.

[75]  J. Heitman,et al.  Rapamycin and Less Immunosuppressive Analogs Are Toxic to Candida albicans and Cryptococcus neoformans via FKBP12-Dependent Inhibition of TOR , 2001, Antimicrobial Agents and Chemotherapy.

[76]  Jie Chen,et al.  Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling , 2001, Science.

[77]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[78]  R. Abraham.  Cell cycle checkpoint signaling through the ATM and ATR kinases. , 2001, Genes & development.

[79]  E. Sausville,et al.  Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[80]  M. Metcalfe,et al.  Rapamycin in transplantation: a review of the evidence. , 2001, Kidney international.

[81]  A. Jaeschke,et al.  Mammalian TOR: A Homeostatic ATP Sensor , 2001, Science.

[82]  J. Blenis,et al.  An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[83]  S K Burley,et al.  Hierarchical phosphorylation of the translation inhibitor 4E-BP1. , 2001, Genes & development.

[84]  J. Barata,et al.  Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). , 2001, Blood.

[85]  P. Frost,et al.  mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. , 2001, Endocrine-related cancer.

[86]  M. V. van Hemert,et al.  14‐3‐3 proteins: key regulators of cell division, signalling and apoptosis , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[87]  R. Valeri,et al.  Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. , 2001, American journal of physiology. Renal physiology.

[88]  E. Pohanka.  New immunosuppressive drugs: an update , 2001, Current opinion in urology.

[89]  Jun Zhu,et al.  14-3-3 proteins; bringing new definitions to scaffolding , 2001, Oncogene.

[90]  A. Gingras,et al.  Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.

[91]  B. Geoerger,et al.  Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. , 2001, Cancer research.

[92]  M. Karin,et al.  Mammalian MAP kinase signalling cascades , 2001, Nature.

[93]  Y. Shiloh,et al.  ATM: genome stability, neuronal development, and cancer cross paths. , 2001, Advances in cancer research.

[94]  R. Abraham.  Identification of TOR Signaling Complexes More TORC for the Cell Growth Engine , 2002, Cell.

[95]  H. Moses,et al.  Rapamycin Potentiates Transforming Growth Factor β-Induced Growth Arrest in Nontransformed, Oncogene-Transformed, and Human Cancer Cells , 2002, Molecular and Cellular Biology.

[96]  L. Aicher,et al.  Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. , 2002, Cancer research.

[97]  C. Proud,et al.  Regulation of mammalian translation factors by nutrients. , 2002, European journal of biochemistry.

[98]  D. Sabatini,et al.  mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.

[99]  T. Golub,et al.  The Immunosuppressant Rapamycin Mimics a Starvation-Like Signal Distinct from Amino Acid and Glucose Deprivation , 2002, Molecular and Cellular Biology.

[100]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[101]  A. Hodges,et al.  Tuberous sclerosis complex tumor suppressor–mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent , 2002, The Journal of cell biology.

[102]  R. Drenan,et al.  The FKBP12‐rapamycin‐associated protein (FRAP) is a CLIP‐170 kinase , 2002, EMBO reports.

[103]  G. Thomas.  The S6 kinase signaling pathway in the control of development and growth. , 2002, Biological research.

[104]  K. Inoki,et al.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.

[105]  J. Crespo,et al.  The TOR-controlled transcription activators GLN3, RTG1, and RTG3 are regulated in response to intracellular levels of glutamine , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[106]  Shile Huang,et al.  Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. , 2002, Current opinion in investigational drugs.

[107]  David J. Kwiatkowski,et al.  Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[108]  J. Crespo,et al.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. , 2002, Molecular cell.

[109]  P. Houghton,et al.  4E-binding Proteins, the Suppressors of Eukaryotic Initiation Factor 4E, Are Down-regulated in Cells with Acquired or Intrinsic Resistance to Rapamycin* , 2002, The Journal of Biological Chemistry.

[110]  O. Hino,et al.  Tsc tumour suppressor proteins antagonize amino-acid–TOR signalling , 2002, Nature Cell Biology.

[111]  J. Avruch,et al.  Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.

[112]  R. Bookstein,et al.  Mutations to CCI-779 PTEN Enhanced Sensitivity of Multiple Myeloma Cells Containing Updated Version , 2002 .

[113]  K. Eguchi,et al.  Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[114]  Tian Xu,et al.  Akt regulates growth by directly phosphorylating Tsc2 , 2002, Nature Cell Biology.

[115]  Christine C. Hudson,et al.  Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.

[116]  G. Thomas,et al.  Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. , 2002, Genes & development.

[117]  J. Blenis,et al.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. , 2002, Molecular cell.

[118]  G. Semenza,et al.  Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling Pathway* , 2002, The Journal of Biological Chemistry.

[119]  Christian Sillaber,et al.  BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. , 2002, Blood.

[120]  Shile Huang,et al.  Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways. , 2003, Cancer research.

[121]  R. Offringa,et al.  Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. , 2003, Blood.

[122]  Shile Huang,et al.  Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). , 2003, Molecular cell.

[123]  Michael N. Hall,et al.  TOR signalling in bugs, brain and brawn , 2003, Nature Reviews Molecular Cell Biology.